Preventative policies in transfusion associated graft versus host disease in the treatment of cancer.
AUTOR(ES)
Webb, D K
RESUMO
Experience of transfusion associated graft versus host disease (TA-GvHD) and current preventative policy in 22 UK children's cancer centres was established by questionnaire. Cellular blood products were irradiated in all centres during bone marrow transplantation, but there was no consensus for children receiving standard chemotherapy. Irradiation dose varied from 1500-5000 cGy and was below 2500 cGy in 12 units. Five cases of TA-GvHD were identified; all five children died.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1030093Documentos Relacionados
- Diagnostic features of transfusion associated graft versus host disease.
- Transfusion associated graft versus host disease in an immunocompetent patient.
- DNA-based HLA typing of nonhematopoietic tissue used to select the marrow transplant donor for successful treatment of transfusion-associated graft-versus-host disease.
- Anti-CD3 Antibody Ameliorates Transfusion-Associated Graft-Versus-Host Disease in a Chemotherapy-Based Mouse Model With Busulfan and Fludarabine
- Cutaneous graft versus host disease.
